Canaccord raised the firm’s price target on Intra-Cellular (ITCI) to $119 from $113 and keeps a Buy rating on the shares. The firm said they are encouraged by continued solid execution and another beat-and-raise on Caplyta in a quarter that typically suffers from seasonality for this class of product.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI: